Research Article

Age-stratified Sero-prevalence and Risk factors of Human Papillomavirus (HPV): Implications for Vaccination in Nigeria

Ajayi, E.O.1*, Agbede, O.O.2, Odeigha, L.O.3
1 Department of Microbiology, Federal University Oye-Ekiti, Ekiti, Nigeria
2 Department of Medical Microbiology and Parasitology, University of Ilorin, Ilorin, Nigeria.
3 Family Medicine Department, University of Ilorin Teaching Hospital, Ilorin, Nigeria.
* Corresponding author: bunmi.ajayi@fuoye.edu.ng
Published: Dec, 2020
DOI: 10.67614/njm.2020.we2a83be
Pages: 5446-5453

Abstract

Human papillomavirus (HPV) is a naked, double-stranded DNA virus that is often responsible for benign lesions of the skin and mucous membranes. Certain strains of HPV have also been implicated in the development of epithelial malignancies. In this study, we investigated age prevalence of IgG antibodies to human papillomavirus16 and 18 among patients of age 1-65 years attending Family Medicine Department of the University of Ilorin Teaching Hospital, Ilorin using ELISA techniques. Out of the 174 consented participants, the prevalence of IgG antibodies to HPV, HPV16 and HPV18 in this study is 3.4%, 0.6% and 1.7% respectively. A seroprevalence of 7.1% in the under 5 age-group was found in this cross sectional study. The correlation between the risk factors and HPV seroprevalence were however not statistically significant. The prevalence of IgG antibody observed also shows that majority of the subjects are still at risk of HPV infection and this highlights the potential roles of massive vaccination to provide herd immunity. Seroprevalence among under-5 class calls for inclusion of HPV vaccination among this age group as against current older vaccination age.

Keywords

Human Papillomavirus IgG antibodies Age Prevalence Vaccine

References

  1. Auwal I.K., Aminu M., Atanda A.T., Tukur J. & Sarkinfada F. (2013) Prevalence and Risk Factors of High Risk Human Papillomavirus infections among Women Attending Gynaecological Clinics in Kano, Northern Nigeria, Bayero. Journal of Pure and Applied Sciences, 6(1):67-71.
  2. Bisi-Onyemaechi A.I., Chikani U.N. & Nduagubam O.C. (2018). Reducing incidence of cervical cancer: knowledge and attitudes of caregivers in Nigerian city to Human Papillomavirus vaccine. Public Health Agenus Cancer, 13:29.
  3. Bodaghi S., Wood L.V., Roby G., Ryder C., Steinberg S.M. & Zheng Z.M. (2005) Could human papillomaviruses be spread through blood? J. Clin. Microbiol. 43(1):5428-5434.
  4. Bruni L., Diaz M., Castellsague M., Ferrer E, Bosch F.X. & de Sanjose S. (2010). Cervical Papillomavirus prevalence in five Continents; Meta-Analysis of million Women with normal cytological findings. The Journal of Infectious Diseases 202(12): 1789-1799.
  5. Bruni L., Barrionuevo-Rosas L., Albero G., Serrano B., Mena M., Gómez D., Muñoz J, Bosch F.X. & de Sanjosé S. (2017). ICO/IARC Information Centre on HPV and Cancer (HPV Information Centre). Human Papillomavirus and Related Diseases in Nigeria. Summary Report.
  6. CDC (2010). FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations for the advisory committee in Immunization Practices (ACIP). MMWR Morb Mortal WWY Rep., 59:626-629.
  7. CDC (2013). Basic Information about HPV and Cancer.
  8. Chew G.K., Cruickshank M.E., Rooney P.H., Miller I.D., Parkin D.E. & Murray G.I (2005). Human papillomavirus 16 infection in adenocarcinoma of the cervix. Br J Cancer, 93(11): 1301-1304.
  9. Clifford G. & Franceschi S (2008). Members of the human papillomavirus type 18 family (alpha-7 species) share a common association with adenocarcinoma of the cervix. Int J Cancer, 122(7):1684-1685.
  10. Cutts F.T., Franceschi S., Goldie S., Castellsague X., de Sanjose S., Garnett G., Edmunds W.J., Claeys P., Goldenthal K.L. Harper D.M. & Markowitz L. (2007). Human papillomavirus and HPV vaccines: a review. Bulletin of the World Health Organisation, 85(9): 649-732.
  11. de Sanjose S., Diaz M., Castellsague X., Clifford G., Bruni L., Munoz N. & de Sanjose F.X. (2007). Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis, 7(7):453-459.
  12. Fadahunsi O.O., Omoniyi-Esan G.O., Bango A.A.F., Esimai O.A., Osiagwu D., Clement F., Adetoye O.V., Bejide K.A. & Iyiola S. (2013). Prevalence of High Risk Oncogenic Human Papillomavirus Types in Cervical smears of Women Attending Well Woman Clinic in Ile Ife, Nigeria. Gynacol Obstet., 3(6):185
  13. Ferlay J., Shin H.R, Bray F., Forman D., Mathers C. & Parkin D.M (2010). Estimate of cancer burden in 2008: GLOBOCAN 2008. Int J Cancer, 127(12):2893-2917
  14. Jayaprakash V., Reid M. & Hatton E (2011). Human papillomavirus types 16 and 18 in epithelial dysplasia of oral cavity and oropharynx: 1985-2010. Oral Oncol, 47 (11):1048-1054.
  15. Newall A.T., Brotherton J.M.L., Quinn H.E., Intyre P.B., Backhouse J., Gilbert L., Esser M.T., Erick J., Bryan J. & Formica N. (2008). Population Seroprevalence of Human Papillomavirus Types 6,11,16 and 18 in Men, Women and Children in Australia. Clin Infect Dis, 46 (11):1647-1655.
  16. Nweke M.C., Okolo C.A, Daous Y. & Esan O.A. (2018). Challenges of Human Papilloma virus Infection and Associated Diseases in Low-Resource Countries. Arch Pathol Lab Med, 142(6):696-699.
  17. Oboma Y.J. & Awworo G.O (2012). Prevalence of Cervical Human Papillomavirus infection among women in Bayelsa, Nigeria. Cont. J Biomed Sci., 6(1):1-3.
  18. Okunade K.S., Nwodu C.M., Oluwole A.Y. & Anoriu R.I. (2017). Prevalence and risk factors for genital high-risk human papillomavirus infection among women attending the out-patient clinics of a university hospital in Lagos, Nigeria. The Pan African Medical Journal, 28:1.
  19. Omoaro A.A., Ashaka O.S., Nasir I.A. & Agbede O.O. (2016). The Burden of Human Papillomavirus Infections Among Women in Nigeria: a Review Update. Journal of Applied Virology, 5:2.
  20. Paul K.S. Chan, Alexander R. Chang, jo L.K.Cheung, Denise P.C Chan, Xu L.Y., Nelson L.S Tang & Augustine F. Cheng (2002). The Journal of Infectious Diseases, 185(1):28-35.
  21. Piras F., Piga M., De Mntis A., Zannou A.R.F., Minerba L., Perra M.T,Murtas D., Atzori M., Pittau M., Maxia C. & Sirigu P. (2011). Prevalence of Human Papillomavirus infection in women in Benin, West Africa. Virol J., 8:514.
  22. Sabeena S., Bhat P., Kamath V. & Arunkama G. (2017). Possible non-sexual modes of transmission of Human Papillomavirus Infection and Associated Diseases in Low-Resources Countries. J. Obstet. Gynacol., 43(3):429-435.
  23. Syrjanen S. & Puranen M.(2000). HPV infections in children; the potential role of maternal transmission. Crit Rev Oral Biol Med, 11(2) 259-274.
  24. Syrjanen K., Shabalova I., Petrovichev N., Kozachenko V., Zakharova T. & Pajanidi J. (2007). Smoking is an independent risk factor for oncogenic human papillomavirus (HPV) infections but not for high-grade cervical intraepithelial neoplasia. Eur J Epidemiol., 22:723–735.
  25. Tiggelaar S.M., Lin M.J., Viscidi R.P., Jia D.M. & Smith J.S. (2012) Age specific human papillomavirus antibody and deoxyribonucleic acid prevalence: a global review. J Adolesc Health, 50(2):110-131.
  26. Van Doorslaer K. (2013). Evolution of the Human Papillomaviridae. Virology, 445(1-2):11-20.
  27. Wang S.S., Schiffman M., Shields T.S., Herrero R., Hildesheim A. & Bratti M.C.I. (2003) Seroprevalence of human papillomavirus-16, -18, -31, and -45 in a population-based cohort of 10000 women in Costa Rica. Br J Cancer. 89:1248-1254.
  28. Winer R.L., Lee S.K., Hughes JP, Adam D.E., Kiviat N.B. & Kotousky L.A. (2003). Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol., 157:218–226.
  29. World Health Organization (2010). Position paper on Human Papillomavirus.
  30. World Health Organization Fact Sheets (2019). Cervical Papillomavirus and Cervical Cancer.
How to Cite

E.O., A., O.O., A., & L.O., O. (2020). Age-stratified Sero-prevalence and Risk factors of Human Papillomavirus (HPV): Implications for Vaccination in Nigeria. Nigerian Journal of Microbiology, 34(2), 5446-5453. https://doi.org/10.67614/njm.2020.we2a83be

A. E.O., A. O.O., and O. L.O., "Age-stratified Sero-prevalence and Risk factors of Human Papillomavirus (HPV): Implications for Vaccination in Nigeria," Nigerian Journal of Microbiology, vol. 34, no. 2, pp. 5446-5453, December 2020. doi: 10.67614/njm.2020.we2a83be

Share this article:
Facebook X / Twitter LinkedIn
Download PDF View Full Text (PDF) Back to Articles